CA3111205C - Dosage nocturne chronique de lasmiditan pour la prevention de la migraine - Google Patents

Dosage nocturne chronique de lasmiditan pour la prevention de la migraine

Info

Publication number
CA3111205C
CA3111205C CA3111205A CA3111205A CA3111205C CA 3111205 C CA3111205 C CA 3111205C CA 3111205 A CA3111205 A CA 3111205A CA 3111205 A CA3111205 A CA 3111205A CA 3111205 C CA3111205 C CA 3111205C
Authority
CA
Canada
Prior art keywords
migraine
lasmiditan
patient
prevention
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3111205A
Other languages
English (en)
Other versions
CA3111205A1 (fr
Inventor
Robert Russell Conley
Gudarz Davar
Kirk Willis Johnson
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from PCT/US2019/049340 external-priority patent/WO2020051137A1/fr
Publication of CA3111205A1 publication Critical patent/CA3111205A1/fr
Application granted granted Critical
Publication of CA3111205C publication Critical patent/CA3111205C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne l'utilisation nocturne chronique de lasmiditan pour la prévention de la migraine, en particulier de la migraine résistante à la thérapie, qui est définie ici comme migraine résistante à au moins deux régimes de traitement ou de prévention en monothérapie et/ou bithérapie préalables.
CA3111205A 2018-09-04 2019-09-03 Dosage nocturne chronique de lasmiditan pour la prevention de la migraine Active CA3111205C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
US62/726,585 2018-09-04
PCT/US2019/049340 WO2020051137A1 (fr) 2018-09-04 2019-09-03 Dosage nocturne chronique de lasmiditan pour la prévention de la migraine

Publications (2)

Publication Number Publication Date
CA3111205A1 CA3111205A1 (fr) 2020-03-12
CA3111205C true CA3111205C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
AU2019336667B2 (en) Chronic nightly dosing of lasmiditan for migraine prevention
Fava et al. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Johnson et al. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence
EP3340971B1 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
Ruggiero et al. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis
CA3062247A1 (fr) Methodes de traitement du syndrome de doose a l'aide de la fenfluramine
Hornig-Rohan et al. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression
Spreckelmeyer et al. Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [18F] fallypride positron emission tomography study
EP3893876A1 (fr) Deutétrabénazine pour le traitement de la dyskinésie dans la paralysie cérébrale
CA3111205C (fr) Dosage nocturne chronique de lasmiditan pour la prevention de la migraine
HK40045255A (en) Chronic nightly dosing of lasmiditan for migraine prevention
HK40045255B (en) Chronic nightly dosing of lasmiditan for migraine prevention
Yeo et al. Oral agents for the management of agitation and agitated delirium in critically ill patients
EA046122B1 (ru) Длительное введение ласмидитана на ночь для профилактики мигрени
Extein et al. Antidepressants: predicting response/maximizing efficacy
Hardan Neurobiology of Autism and Other Pervasive Developmental Disorders: Basic Mechanisms and Therapeutic Interventions
Reisner et al. Reboxetine (PNU-155950E) Versus Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders
Cooper Psychopharmacology and physical treatments
Froeschke et al. Reboxetine (PNU-155950E) vs. placebo in the treatment of major depressive disorder resistant to fluoxetine
Sommer et al. Naturalistic Setting
HK40026552A (en) Methods of treating doose syndrome using fenfluramine